4.7 Article

In vitro activity of new artemisinin derivatives against Plasmodium falciparum clinical isolates from Gabon

Journal

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 37, Issue 5, Pages 485-488

Publisher

ELSEVIER
DOI: 10.1016/j.ijantimicag.2010.12.022

Keywords

Malaria; Artemisinin; Plasmodium falciparum

Funding

  1. University of Tubingen (Germany)
  2. Medical Research Unit of the Albert Schweitzer Hospital (Lambarene, Gabon)

Ask authors/readers for more resources

Nowadays, artemisinins are the mainstay of malaria treatment, but initial indications of resistance against clinically used derivatives are present. In this study, ten new artemisinin derivatives were tested in vitro against Plasmodium falciparum laboratory strains as well as clinical isolates from Gabon. All derivatives were highly active, with 50% inhibitory concentrations (IC50 values) < 13nM in the clinical isolates. The activity of one fluoro-containing derivative did not correlate with that of the parent compound, suggesting a different activity profile. New artemisinin derivatives with different activity profiles are of special interest as they represent an important class of candidates for pre-clinical testing in clinical parasite isolates adapted to currently used artemisinins, since derivatisation is one possible strategy to prolong the clinical usefulness of this important class of antimalarials. (C) 2011 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Resistance patterns among drug-resistant tuberculosis patients and trends-over-time analysis of national surveillance data in Gabon, Central Africa

Jabar Babatunde Pacome Achimi Agbo Abdul, Bayode Romeo Adegbite, Micheska Epola Dibamba Ndanga, Jean Ronald Edoa, Rhett Chester Mevyann, Guy Rogue Arnault Ibinda Mfoumbi, Tshisekedi Jean de Dieu, Jocelyn Mahoumbou, Christopher Mebiame Biyogho, Sankarganesh Jeyaraj, Stefan Niemann, Bertrand Lell, Peter Gottfried Kremsner, Abraham Sunday Alabi, Ayola Akim Adegnika, Martin Peter Grobusch

Summary: The increasing incidence of MDR-TB infection in Gabon is alarming, especially among individuals aged 25-35. There is a need for improvement in case finding and contact tracing strategies for treatment-naive MDR-TB patients.

INFECTION (2023)

Article Medicine, Research & Experimental

Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials

Oriol Mitja, Gilmar Reis, David R. Boulware, Adam M. Spivak, Ammar Sarwar, Christine Johnston, Brandon Webb, Michael D. Hill, Davey Smith, Peter Kremsner, Marla Curran, David Carter, Jim Alexander, Marc Corbacho, Todd C. Lee, Katherine Huppler Hullsiek, Emily G. McDonald, Rachel Hess, Michael Hughes, Jared M. Baeten, Ilan Schwartz, Luanne Metz, Lawrence Richer, Kara W. Chew, Eric Daar, David Wohl, Michael Dunne

Summary: This study conducted a pooled analysis of individual participant data from 11 randomized controlled trials to evaluate the efficacy of hydroxychloroquine (HCQ) in outpatients with mild COVID-19. The results suggest that HCQ does not show significant effects on viral clearance and hospitalization rate, and therefore, the use of HCQ in mild COVID-19 outpatients should be discontinued to reduce the risk of disease progression.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Editorial Material Immunology

Editorial: Puzzle pieces from malaria vaccine clinical trials

Nirianne Marie Q. Palacpac, Alfred B. Tiono, Benjamin Mordmuller, Takafumi Tsuboi

FRONTIERS IN IMMUNOLOGY (2023)

Article Infectious Diseases

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

Merel J. Smit, Adam F. Sander, Maud B. P. A. Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G. Kremsner, Rob ter Heine, Heiman F. Wertheim, Manja Idorn, Alexander P. Underwood, Alekxander Binderup, Santseharay Ramirez, Jens Bukh, Max Soegaard, Sayit M. Erdogan, Tobias Gustavsson, Stine Clemmensen, Thor G. Theander, Lancet Microbe, Ali Salanti, Mette Hamborg, Willem A. de Jongh, Matthew B. B. McCall, Morten A. Nielsen, Benjamin G. Mordmuller

Summary: A clinical trial was conducted in the Netherlands to test a cVLP-based COVID-19 vaccine. The results showed that the vaccine exhibited high immunogenicity at antigen levels of 25-70 mu g and had high virus neutralization activity against major SARS-CoV-2 variants.

LANCET MICROBE (2023)

Article Medicine, Research & Experimental

Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies

Opeyemi Ernest Oludada, Giulia Costa, Clare Burn Aschner, Anna S. Obraztsova, Katherine Prieto, Caterina Canetta, Stephen L. Hoffman, Peter G. Kremsner, Benjamin Mordmueller, Rajagopal Murugan, Jean-Philippe Julien, Elena A. Levashina, Hedda Wardemann

Summary: The central repeat and junction domain of Plasmodium falciparum circumsporozoite protein (PfCSP) were studied to guide malaria vaccine design using monoclonal antibodies (mAbs). The study describes the molecular characteristics and protective potential of 73 germline and mutated human mAbs against the highly immunogenic PfCSP C-terminal domain.

EMBO MOLECULAR MEDICINE (2023)

Article Virology

RT-PCR-based assessment of the SD Bioline Rota/Adeno Antigen-based test in infants with and without diarrhea

Gedeon Prince Manouana, Paul Alvyn Nguema-Moure, Alexandru Tomazatos, Moustapha Nzamba Maloum, C. -Thomas Bock, Peter G. G. Kremsner, Thirumalaisamy P. P. Velavan, Akim Ayola Adegnika, Sandra Niendorf

Summary: This study aimed to evaluate the performance of the rapid rotavirus test compared to the one-step RT-qPCR method. The results showed that the rapid test had high sensitivity and was suitable for detecting rotavirus A in patients with gastroenteritis, especially in low-income countries.

VIROLOGY JOURNAL (2023)

Article Immunology

Whole genome analysis of two sympatric human Mansonella: Mansonella perstans and Mansonella sp DEUX

Miriam Rodi, Caspar Gross, Thaisa Lucas Sandri, Lilith Berner, Marina Marcet-Houben, Ersoy Kocak, Michaela Pogoda, Nicolas Casadei, Carsten Koehler, Andrea Kreidenweiss, Selidji Todagbe Agnandji, Toni Gabaldon, Stephan Ossowski, Jana Held

Summary: This study investigated the relationship between Mansonella perstans and a potential new species called Mansonella sp DEUX in Gabon. By screening individuals in the area and generating whole genome data, it was found that Mansonella sp DEUX is a new Mansonella species. The availability of whole genome data will facilitate further research on these species.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Letter Pediatrics

Saliva and Plasma Antibody Levels in Children andAdolescentsAfter Primary Infection With Omicron Variants of SARS-CoV-2 Infection inGermany

Constanze Heinzel, Yudi T. Pinilla, Ayla Binder, Peter G. Kremsner, Jana Held, Rolf Fendel, Andrea Kreidenweiss

JAMA PEDIATRICS (2023)

Article Microbiology

Low Prevalence of Plasmodium falciparum Histidine-Rich Protein 2 and 3 Gene Deletions-A Multiregional Study in Central and West Africa

Tina Krueger, Moses Ikegbunam, Abel Lissom, Thaisa Lucas Sandri, Jacques Dollon Mbama Ntabi, Jean Claude Djontu, Marcel Tapsou Baina, Romeo Aime Laclong Lontchi, Moustapha Maloum, Givina Zang Ella, Romuald Agonhossou, Romaric Akoton, Luc Djogbenou, Steffen Borrmann, Jana Held, Francine Ntoumi, Ayola Akim Adegnika, Peter Gottfried Kremsner, Andrea Kreidenweiss

Summary: The frequency of pfhrp2 and pfhrp3 deleted strains in Central and West Africa was assessed and found to be low, indicating a low risk of false-negative results in HRP2-based rapid diagnostic tests. However, continuous monitoring is crucial due to the potential for rapid changes in this scenario to ensure the suitability of RDTs for malaria diagnostics.

PATHOGENS (2023)

Article Infectious Diseases

Prostration and the prognosis of death in African children with severe

Selidji Agnandji, Mario Recker, Benjamin Mordmueller, Stephan Gloeckner, Akim A. Adegnika, Bertrand Lell, Lucas Otieno, Walter Otieno, Seth Owusu-Agyei, Kwaku P. Asante, Tsiri Agbenyega, Daniel Ansong, Eusebio Macete, Pedro Aide, Hermann Sorgho, Halidou Tinto, Neema Mturi, John P. A. Lusingu, Samwel Gesase, Irving Hoffman, Nahya Salim Masoud, Charles R. Newton, Kalifa Bojang, Gerard Krause, Peter Gottfried Kremsner

Summary: Malaria remains a major cause of hospitalization in children in sub-Saharan Africa. Rapid risk stratification upon admission is crucial for optimal medical care and improved prognosis. While coma, deep breathing, and to some extent severe anemia are established predictors of malaria-related death, the significance of assessing prostration for risk stratification is not yet certain.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults - a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial

Dorothea Ekoka Mbassi, Ghyslain Mombo-Ngoma, Jana Held, Dearie Glory Okwu, Wilfrid Ndzebe-Ndoumba, Laura Charlotte Kalkman, Franck Aurelien Ekoka Mbassi, Lais Pessanha de Carvalho, Juliana Inoue, Malik Azeez Akinosho, Lia Betty Dimessa Mbadinga, Emmanuel Koffi Yovo, Benjamin Mordmueller, Peter Gottfried Kremsner, Ayola Akim Adegnika, Michael Ramharter, Rella Zoleko-Manego

Summary: This study assessed the tolerability and efficacy of ivermectin in Gabonese adults with P. falciparum infections. The results showed that ivermectin reduced the asexual parasites similarly to placebo, indicating its potential as a treatment for asymptomatic P. falciparum infections.

EBIOMEDICINE (2023)

Letter Pediatrics

Saliva and Plasma Antibody Levels in Children and Adolescents After Primary Infection With Omicron Variants of SARS-CoV-2 Infection in Germany

Constanze Heinzel, Yudi T. Pinilla, Ayla Binder, Peter G. Kremsner, Jana Held, Rolf Fendel, Andrea Kreidenweiss

Summary: This cross-sectional study examines IgG antibody levels in children and adolescents in Germany after SARS-CoV-2 infection.

JAMA PEDIATRICS (2023)

Article Public, Environmental & Occupational Health

Spatiotemporal variation in risk of Shigella infection in childhood: a global risk mapping and prediction model using individual participant data

Hamada S. Badr, Josh M. Colston, Nhat-Lan H. Nguyen, Yen Ting Chen, Eleanor Burnett, Syed Asad Ali, Ajit Rayamajhi, Syed M. Satter, Nguyen Van Trang, Daniel Eibach, Ralf Krumkamp, Juergen May, Ayola Akim Adegnika, Gedeon Prince Manouana, Peter Gottfried Kremsner, Roma Chilengi, Luiza Hatyoka, Amanda K. Debes, Jerome Ateudjieu, Abu S. G. Faruque, M. Jahangir Hossain, Suman Kanungo, Karen L. Kotloff, Inacio Mandomando, M. Imran Nisar, Richard Omore, Samba O. Sow, Anita K. M. Zaidi, Nathalie Lambrecht, Bright Adu, Nicola Page, James A. Platts-Mills, Cesar Mavacala Freitas, Tuula Pelkonen, Per Ashorn, Kenneth Maleta, Tahmeed Ahmed, Pascal Bessong, Zulfiqar A. Bhutta, Carl Mason, Estomih Mduma, Maribel P. Olortegui, Pablo Penataro Yori, Aldo A. M. Lima, Gagandeep Kang, Jean Humphrey, Robert Ntozini, Andrew J. Prendergast, Kazuhisa Okada, Warawan Wongboot, Nina Langeland, Sabrina J. Moyo, James Gaensbauer, Mario Melgar, Matthew Freeman, Anna N. Chard, Vonethalom Thongpaseuth, Eric Houpt, Benjamin F. Zaitchik, Margaret N. Kosek

Summary: This study aimed to model the spatiotemporal variation in paediatric Shigella infection and predict its prevalence across low-income and middle-income countries. The findings revealed the association between Shigella and climatological factors, with sub-Saharan Africa being a high-risk region for transmission. These findings can guide prioritization of populations for future vaccine trials and campaigns.

LANCET GLOBAL HEALTH (2023)

Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)